CN104470517B - 注射用抗生素制剂及其使用方法 - Google Patents

注射用抗生素制剂及其使用方法 Download PDF

Info

Publication number
CN104470517B
CN104470517B CN201380038000.4A CN201380038000A CN104470517B CN 104470517 B CN104470517 B CN 104470517B CN 201380038000 A CN201380038000 A CN 201380038000A CN 104470517 B CN104470517 B CN 104470517B
Authority
CN
China
Prior art keywords
composition
pnt
agent
ot11pntrtu
preparation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201380038000.4A
Other languages
English (en)
Chinese (zh)
Other versions
CN104470517A (zh
Inventor
F·A·阿拉维
O·博克
R·贾殷
K·南加
I·G·图克
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ylanco New Zealand
Original Assignee
Bayer New Zealand Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49949085&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN104470517(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from NZ613138A external-priority patent/NZ613138B2/en
Application filed by Bayer New Zealand Ltd filed Critical Bayer New Zealand Ltd
Publication of CN104470517A publication Critical patent/CN104470517A/zh
Application granted granted Critical
Publication of CN104470517B publication Critical patent/CN104470517B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/14—Drugs for genital or sexual disorders; Contraceptives for lactation disorders, e.g. galactorrhoea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Biochemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Biophysics (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CN201380038000.4A 2012-07-17 2013-07-16 注射用抗生素制剂及其使用方法 Active CN104470517B (zh)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
NZ601299 2012-07-17
NZ60129912 2012-07-17
NZ61017513 2013-05-03
NZ610175 2013-05-03
NZ613138A NZ613138B2 (en) 2013-07-12 Injectable antibiotic formulations and their methods of use
NZ613138 2013-07-12
PCT/NZ2013/000123 WO2014014363A1 (en) 2012-07-17 2013-07-16 Injectable antibiotic formulations and their methods of use

Publications (2)

Publication Number Publication Date
CN104470517A CN104470517A (zh) 2015-03-25
CN104470517B true CN104470517B (zh) 2018-12-18

Family

ID=49949085

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201380038000.4A Active CN104470517B (zh) 2012-07-17 2013-07-16 注射用抗生素制剂及其使用方法

Country Status (30)

Country Link
US (1) US10376585B2 (enExample)
EP (1) EP2874624B8 (enExample)
JP (1) JP6189437B2 (enExample)
KR (1) KR102113822B1 (enExample)
CN (1) CN104470517B (enExample)
AU (1) AU2013290826B2 (enExample)
BR (1) BR112014031083B1 (enExample)
CA (1) CA2875351C (enExample)
CL (1) CL2014003423A1 (enExample)
CO (1) CO7240359A2 (enExample)
CR (1) CR20140550A (enExample)
DK (1) DK2874624T3 (enExample)
DO (1) DOP2014000288A (enExample)
ES (1) ES2752034T3 (enExample)
HR (1) HRP20191730T1 (enExample)
HU (1) HUE046427T2 (enExample)
IL (1) IL236713B (enExample)
LT (1) LT2874624T (enExample)
MX (2) MX387668B (enExample)
MY (1) MY172561A (enExample)
NI (1) NI201400152A (enExample)
PH (1) PH12014502716A1 (enExample)
PL (1) PL2874624T3 (enExample)
PT (1) PT2874624T (enExample)
RU (1) RU2643327C2 (enExample)
SI (1) SI2874624T1 (enExample)
SV (1) SV2014004882A (enExample)
UA (1) UA118654C2 (enExample)
WO (1) WO2014014363A1 (enExample)
ZA (1) ZA201409322B (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014098624A1 (en) * 2012-12-20 2014-06-26 Alleva Animal Health Limited Veterinary injectable formulations

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2087236A (en) * 1980-11-17 1982-05-26 Leo Pharm Prod Ltd Pharmaceutical preparations containing a 6 beta -halopenicillanic acid
US4594246A (en) * 1979-05-21 1986-06-10 Leo Pharmaceutical Products Pharmaceutically-acceptable amine salts of 6-β-halopenicillanic acids
CN1517090A (zh) * 2003-01-20 2004-08-04 王玉万 含抗菌药物的兽用混悬注射剂或乳剂
WO2010102196A2 (en) * 2009-03-05 2010-09-10 Insite Vision Incorporated Controlled-release ophthalmic vehicles

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE51516B1 (en) * 1980-10-06 1987-01-07 Leo Pharm Prod Ltd 1,1-dioxapenicillanoyloxymethyl 6-(d-alpha-amino-alpha-phenylacetamido)penicillanate napsylate
IL64009A (en) 1980-10-31 1984-09-30 Rech Applications Therap Crystalline 1,1-dioxopenicillanoyloxymethyl 6-(d-alpha-amino-alpha-phenylacetamido)penicillanate tosylate hydrates,their production and pharmaceutical compositions containing them
EP0115001B1 (de) 1982-12-28 1988-06-15 Bayer Ag Stabile Aminoglykosid-Penicillin-Injektionsformulierungen
US5736151A (en) 1996-12-09 1998-04-07 Pharmacia & Upjohn Company Antibiotic oil suspensions
CH693625A5 (it) * 1999-02-18 2003-11-28 Inpharma Sa Composizioni farmaceutiche contenenti composti ad attività promotrice di assorbimento di principi attivi.
US20040022815A1 (en) 2002-08-05 2004-02-05 Orchid Health Care Novel pharmaceutical composition of ceftiofur
KR20040015622A (ko) 2002-08-13 2004-02-19 대한뉴팜(주) 세프티오푸르나트륨을 활성성분으로 함유하는 현탁주사액조성물
US6911441B2 (en) 2002-12-16 2005-06-28 Akzo Nobel N.V. Prolonged release pharmaceutical composition
US20050143347A1 (en) * 2003-12-22 2005-06-30 Aventis Pharma Deutschland Gmbh Medicinal lipolysis of accumulations of fat
DE102004025324A1 (de) * 2004-05-19 2005-12-08 Boehringer Ingelheim Vetmedica Gmbh Flüssige Zubereitung für die Veterinärmedizin, Verfahren zu deren Herstellung und deren Verwendung
US20060142234A1 (en) 2004-12-23 2006-06-29 Guohua Chen Injectable non-aqueous suspension
US8679540B2 (en) * 2006-06-09 2014-03-25 Flamel Technologies Pharmaceutical formulations for the prolonged release of active principle(s), and their applications, especially therapeutic applications
ES2716474T3 (es) * 2007-10-26 2019-06-12 Avivagen Inc Composiciones y métodos para mejorar la respuesta inmunitaria
PL2294012T3 (pl) * 2008-05-07 2014-12-31 Salix Pharmaceuticals Inc Podawanie środka czyszczącego jelito i antybiotyku w leczeniu choroby jelit
WO2010138918A1 (en) * 2009-05-29 2010-12-02 Pacira Pharmaceuticals, Inc. Hyaluronidase as an adjuvant for increasing the injection volume and dispersion of large diameter synthetic membrane vesicles containing a therapeutic agent
CN101822637A (zh) * 2009-12-31 2010-09-08 天津瑞普生物技术股份有限公司 一种含有β-内酰胺类抗生素的混悬注射剂
US20110223208A1 (en) * 2010-03-09 2011-09-15 Beth Hill Non-Aqueous High Concentration Reduced Viscosity Suspension Formulations
DE102010015143A1 (de) 2010-04-16 2011-10-20 Cts Chemical Industries Ltd. Stabile flüssige ölige gebrauchsfertige Formulierungen, Herstellung davon und Verwendung davon
MX355769B (es) * 2011-06-23 2018-04-30 Bayer New Zealand Ltd Una composición antiparasitaria y método de tratamiento.
WO2013095166A1 (en) 2011-12-23 2013-06-27 Bayer New Zealand Limited Antibiotic formulations
CN110604819A (zh) * 2012-02-27 2019-12-24 拜耳新西兰有限公司 控制释放组合物及其使用方法

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4594246A (en) * 1979-05-21 1986-06-10 Leo Pharmaceutical Products Pharmaceutically-acceptable amine salts of 6-β-halopenicillanic acids
GB2087236A (en) * 1980-11-17 1982-05-26 Leo Pharm Prod Ltd Pharmaceutical preparations containing a 6 beta -halopenicillanic acid
CN1517090A (zh) * 2003-01-20 2004-08-04 王玉万 含抗菌药物的兽用混悬注射剂或乳剂
WO2010102196A2 (en) * 2009-03-05 2010-09-10 Insite Vision Incorporated Controlled-release ophthalmic vehicles

Also Published As

Publication number Publication date
WO2014014363A1 (en) 2014-01-23
PH12014502716B1 (en) 2015-02-02
KR20150036092A (ko) 2015-04-07
CA2875351C (en) 2021-08-31
IL236713A0 (en) 2015-02-26
CL2014003423A1 (es) 2015-04-17
LT2874624T (lt) 2019-12-10
BR112014031083B1 (pt) 2021-06-15
MX387668B (es) 2025-03-18
CN104470517A (zh) 2015-03-25
HRP20191730T1 (hr) 2019-12-13
MX358248B (es) 2018-08-10
UA118654C2 (uk) 2019-02-25
AU2013290826B2 (en) 2018-10-18
RU2643327C2 (ru) 2018-01-31
MX2014015927A (es) 2015-03-03
BR112014031083A2 (pt) 2017-06-27
IL236713B (en) 2018-05-31
NI201400152A (es) 2015-03-27
EP2874624A1 (en) 2015-05-27
ES2752034T3 (es) 2020-04-02
EP2874624B1 (en) 2019-08-21
DOP2014000288A (es) 2015-02-15
EP2874624B8 (en) 2019-10-02
AU2013290826A1 (en) 2015-01-15
MY172561A (en) 2019-12-03
CR20140550A (es) 2015-02-05
HUE046427T2 (hu) 2020-03-30
KR102113822B1 (ko) 2020-05-22
ZA201409322B (en) 2015-12-23
DK2874624T3 (da) 2019-11-11
JP6189437B2 (ja) 2017-08-30
CO7240359A2 (es) 2015-04-17
RU2015105251A (ru) 2016-09-10
SI2874624T1 (sl) 2020-02-28
SV2014004882A (es) 2016-11-11
JP2015522608A (ja) 2015-08-06
CA2875351A1 (en) 2014-01-23
PH12014502716A1 (en) 2015-02-02
EP2874624A4 (en) 2015-12-02
US10376585B2 (en) 2019-08-13
PL2874624T3 (pl) 2020-07-27
PT2874624T (pt) 2019-11-04
US20150174248A1 (en) 2015-06-25

Similar Documents

Publication Publication Date Title
JP7312523B2 (ja) フルベストラント配合物およびその使用方法
US20140348852A1 (en) Method for making precipitated particles
CN104470517B (zh) 注射用抗生素制剂及其使用方法
EP4393480A1 (en) Lyophilized formulation solution and lyophilized formulation, and method and use thereof
CN104507475B (zh) 注射用抗生素制剂及其使用方法
KR20250160163A (ko) 용액, 동결건조 제형, 동결건조 제형 단위 패키지, 주사제, 및 주사제 제조 방법
CN105560182A (zh) 注射用卡巴他赛组合物及其制备方法
TWI631948B (zh) 可注射型抗生素配方及其使用方法
AU2023211896B2 (en) Granules comprising progerinin, and sachets using same
EP4445896A1 (en) Nanosuspension containing progerinin, and preparation method therefor
NZ613138B2 (en) Injectable antibiotic formulations and their methods of use
NZ629041A (en) Injectable antibiotic formulations and their methods of use
NZ613240B2 (en) Injectable antibiotic formulations and their methods of use

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant
TR01 Transfer of patent right

Effective date of registration: 20250801

Address after: Oakland, New Zealand

Patentee after: Ylanco New Zealand

Country or region after: Xin Xilan

Address before: New Zealand Hamilton

Patentee before: BAYER NEW ZEALAND Ltd.

Country or region before: Xin Xilan

TR01 Transfer of patent right